reported that the triple combination of vascular-targeted photodynamic therapy (VTP), PD-1 inhibitors, and OX40 agonists achieved superior tumor growth suppression and prolonged survival compared to VTP or immunotherapy alone (35). This evidence concerns the gene TNFRSF4 and neoplasm.